Cite
Schakenraad A, Hashemi S, Twisk J, et al. The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors. Lung Cancer. 2021;162:36-41doi: 10.1016/j.lungcan.2021.10.002.
Schakenraad, A., Hashemi, S., Twisk, J., Houda, I., Ulas, E., Daniels, J. M. A., Veltman, J., & Bahce, I. (2021). The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors. Lung cancer (Amsterdam, Netherlands), 16236-41. https://doi.org/10.1016/j.lungcan.2021.10.002
Schakenraad, Alexandra, et al. "The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors." Lung cancer (Amsterdam, Netherlands) vol. 162 (2021): 36-41. doi: https://doi.org/10.1016/j.lungcan.2021.10.002
Schakenraad A, Hashemi S, Twisk J, Houda I, Ulas E, Daniels JMA, Veltman J, Bahce I. The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors. Lung Cancer. 2021 Dec;162:36-41. doi: 10.1016/j.lungcan.2021.10.002. Epub 2021 Oct 11. PMID: 34666276.
Copy
Download .nbib